1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

Generic Industry Not Sold On Benefits Of FDA Emerging Technology Program

 
• By Joanne S. Eglovitch

FDA’s calls for more generic industry participation in its Emerging Technology Program fell on deaf ears at recent meeting, with several complaining about the costs and value of investing in new manufacturing technologies.

3D
Generic Industry Presses FDA For More Incentives To Participate In Emerging Technology Program • Source: Shutterstock

Pharmaceutical industry officials attending the Association for Accessible Medicines' 4-6 November GRx-Biosims meeting in North Bethesda, MD, said that there are a number of factors that preclude their participation in the US Food and Drug Administration's Emerging Technology Program despite the benefits the head of the program said emerging technologies can deliver, such as more robust manufacturing processes and reduced risk of drug shortages.

Challenges include the high cost of developing these technologies, the lack of outside support, and uncertainty as to whether these...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

Homework Avoidance: US FDA’s Upfront Effort For CMC Pilot Dissuades Participation

 
• By Bridget Silverman

The clarity on quality topics provided by the CMC Readiness Pilot (CDRP) is worth the work of preparing a comprehensive development review and multiple meetings, participants from Intellia, Bicycle Therapeutics and Bristol Myers Squibb said during a Duke Margolis meeting.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

More from Compliance

Homework Avoidance: US FDA’s Upfront Effort For CMC Pilot Dissuades Participation

 
• By Bridget Silverman

The clarity on quality topics provided by the CMC Readiness Pilot (CDRP) is worth the work of preparing a comprehensive development review and multiple meetings, participants from Intellia, Bicycle Therapeutics and Bristol Myers Squibb said during a Duke Margolis meeting.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US Confirms 15% Tariff On Japanese Drugs, But Confusion Lingers

 
• By Lisa Takagi

After tough negotiations which won the country a lower US levy on pharmaceuticals, there still appears to be some confusion within the Japanese government following President Trump's latest announcement on global pharma tariffs.